Submitted by Massachusetts Life Sciences Center:
MBL International Corporation, a leading life science company focused on providing high quality, innovative, solutions-based products for both life science research and clinical diagnostics, and SCIVAX USA, INC., a leading provider of 3D cell culture solutions based on the original “Micro-Patterned Surface Technology,” are delighted to announce the official opening of a new shared laboratory in Woburn, an emerging life science innovation district in the Greater Boston area.
MBL International Corporation and SCIVAX USA, INC. hosted a ribbon-cutting ceremony today to mark the opening of their new facility. The ceremony was held in collaboration with the Massachusetts Life Sciences Center (MLSC) and MassBio. A number of industry and government officials participated, including the Consul General of Japan in Boston.
“Massachusetts leads the world in life sciences thanks to our growth strategy of investing in education, innovation and infrastructure, and looking out into the global economy, not just in,” said Governor Deval Patrick. “We look forward to working with Scivax USA and MBL International as they open their first U.S. laboratory facility here in the Commonwealth.”
“The lab represents a new chapter in the development of MBL International and SCIVAX USA. Our researchers now have the facilities and resources to extend both company’s research and development support capabilities,” said Kimimasa Yamada, CEO of MBL International Corporation.
“The lab is not only enhancing the R&D capabilities of both companies, but is also expected to become a frontline base for the innovative collaborators of both companies in Japan, to enter the U.S. market,” said Hiromi Miura, President of SCIVAX USA.
The 3,000 square-foot immunological and molecular biological R&D facility houses both MBL International and SCIVAX USA’s state-of-the art imaging equipment, including a GE InCell2200 and Flow Cytometer. In addition to imaging instrumentation, the facility is outfitted with a cell culture capability focused on novel three-dimensional cell culture technology.
“On behalf of the team at the Massachusetts Life Sciences Center, congratulations to Scivax USA and MBL International on the opening of their first U.S. wet laboratory,” said Susan Windham-Bannister, Ph.D., President & CEO of the MLSC. “The expanded presence of these companies in Massachusetts will enhance our life sciences ecosystem, and further strengthen the growing business ties between Massachusetts and Japan.”
“We are very pleased that our growing business relationship with Japan is continuing to bear fruit, a relationship that was further developed through the recent Governor led trade mission to the region,” said Richard Elam, Executive Director of the Massachusetts Office of International Trade & Investment. “From the two recent MOU signings between the Commonwealth and Japan’s Kanagawa Prefecture and the Japanese External Trade Organization to today’s announcement of the Scivax/MBL establishment in Massachusetts, we are seeing a significant increase in the already vibrant economic relationship between Massachusetts and Japan.”
MBL International was established in a suburb of Boston in 1993 and has since been a leading life science company focused on providing high quality, innovative, solution-based products for both life science research and clinical diagnostics in North America, South America, Europe and other countries. In the field of life science research, the Company sells distinct antibodies and biological reagents in high demand by researchers. MBLI has recently started manufacturing and selling globally MHC Tetramer products which can detect antigen-specific T cells. In the epigenomic area, the Company also plans to launch new antibodies which recognize characteristic modified nucleic acids. Regarding in vitro diagnostics, MBLI sells indirect immunofluorescence products for autoimmune and infectious diseases and ELISA products for autoimmune disease.
SCIVAX USA opened their sales office in Woburn in October 2010, and has steadily increased the sales of their 3D cell culture ware “NanoCulture Plate” in the U.S. market. The opening of this new laboratory facility is expected to add assay development and contract research capabilities to the company, which is expected to accelerate its growth and presence in the life science market.
MBL International and SCIVAX USA’s new facility is located at 3-G Gill St. in Woburn.